
    
      Design and Setting: 84 day (D84), double-blind, randomized, placebo (PL)-controlled clinical
      trial conducted in an academic tertiary care center.

      Patients: Non-DM2 Controls (n=15); participants with DM2 receiving PL (n=13) or DOX (n=11).

      Interventions: All participants were evaluated at day 1 (D1); those with DM2 were also
      evaluated at D84 after DOX 100mg twice daily or PL.
    
  